Endothelial dysfunction and subclinical hypothyroidism: a brief review

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Internal Medicine

Background:

• Subclinical hypothyroidism (SH) is defined by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (T4) and triiodothyronine (T3) levels.
• The cardiovascular implications of SH remain a subject of ongoing research and debate.
• SH is increasingly recognized as a potential contributor to endothelial dysfunction and atherosclerosis.

Purpose of the Study:

• To investigate the association between subclinical hypothyroidism and cardiovascular disease.
• To explore the mechanisms by which SH may affect vascular health.
• To evaluate the potential benefits of thyroid hormone replacement therapy in SH patients.

Main Methods:

• Review of existing literature on subclinical hypothyroidism and cardiovascular outcomes.
• Analysis of studies examining endothelial function, lipid profiles, blood pressure, and inflammatory markers in SH.
• Assessment of research on the effects of thyroid hormone replacement therapy.

Main Results:

• SH is linked to endothelial dysfunction, increased LDL-cholesterol, elevated diastolic blood pressure, and heightened C-reactive protein.
• SH is associated with reduced nitric oxide bioavailability and increased angiotensin receptor expression.
• Thyroid hormone replacement therapy demonstrated improvements in these cardiovascular risk factors.

Conclusions:

• Subclinical hypothyroidism contributes to cardiovascular risk through both traditional and non-traditional pathways.
• SH negatively impacts vascular function and promotes atherosclerosis.
• Thyroid hormone replacement therapy may mitigate cardiovascular risks associated with SH.